Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein biased mu-opioid receptor agonists in male and female Sprague–Dawley rats
Rationale G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein bias...
Saved in:
| Published in | Psychopharmacology Vol. 241; no. 12; pp. 2453 - 2469 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.12.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Rationale
G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.
Objectives
The aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.
Methods
In the self-administration study, four separate groups of Sprague–Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.
Results
All MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.
Conclusion
The present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics. |
|---|---|
| AbstractList | Rationale
G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.
Objectives
The aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.
Methods
In the self-administration study, four separate groups of Sprague–Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.
Results
All MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.
Conclusion
The present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics. G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.RATIONALEG-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.The aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.OBJECTIVESThe aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.In the self-administration study, four separate groups of Sprague-Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.METHODSIn the self-administration study, four separate groups of Sprague-Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.All MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.RESULTSAll MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.The present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics.CONCLUSIONThe present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics. RationaleG-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.ObjectivesThe aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.MethodsIn the self-administration study, four separate groups of Sprague–Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.ResultsAll MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.ConclusionThe present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics. G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints. The aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats. In the self-administration study, four separate groups of Sprague-Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography. All MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner. The present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics. |
| Author | Pareek, Tanya Pham, Loc M. Vallender, Eric J. Blough, Bruce E. Zamarripa, C. Austin Freeman, Kevin B. Schrock, Hayley M. Sufka, Kenneth J. |
| Author_xml | – sequence: 1 givenname: C. Austin orcidid: 0000-0002-6426-8984 surname: Zamarripa fullname: Zamarripa, C. Austin email: czamarr2@jhmi.edu organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center – sequence: 2 givenname: Tanya orcidid: 0000-0001-9133-0811 surname: Pareek fullname: Pareek, Tanya organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center – sequence: 3 givenname: Loc M. surname: Pham fullname: Pham, Loc M. organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center – sequence: 4 givenname: Bruce E. surname: Blough fullname: Blough, Bruce E. organization: School of Pharmacy – sequence: 5 givenname: Hayley M. surname: Schrock fullname: Schrock, Hayley M. organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center – sequence: 6 givenname: Eric J. surname: Vallender fullname: Vallender, Eric J. organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center – sequence: 7 givenname: Kenneth J. surname: Sufka fullname: Sufka, Kenneth J. organization: Department of Psychology, University of Mississippi – sequence: 8 givenname: Kevin B. surname: Freeman fullname: Freeman, Kevin B. organization: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39333403$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9uFSEUxompsbfVF3BhSNy4cBQG5g9Lc9Vq0sSFuiZnZg5XmhkYgdHene_g6_g0PonMvW1Muigb4OT3fRzgOyMnzjsk5ClnrzhjzevIWMlFwUpZsLpWrLh-QDZcirIoWVOekA1jQhSCV-0pOYvxiuUhW_mInAolhJBMbMifrZ9mCDZ6R72h6RvSgNYZH3rrdi8puGSd722Pc7I_cC0MmYizDZB82NMB57yNmaNoDPYprj5z8Mmn_Wx7GA-Si2ItZWfaWYg40Gkp_Gy9Xd1Wcx8o7LyzMRtkaoIRD0KDh-XnOcBuwb-_fr-FnyPuaT4-PiYPDYwRn9zM5-Tr-3dfth-Ky08XH7dvLoteNFUqFAIYZKapeVe3Zc3LQYGopOo6hRI7qbBtANtK9qZCxXkJCB0oiU3LBUNxTl4cffMdvi8Yk55s7HEcwaFfohac5wdXTLGMPr-DXvkluNxdpjJSMcHaTD27oZZuwkHPwU4Q9vr2XzLQHoE--BgDGt3bBMl6lwLYUXOm1wjoYwR0joA-REBfZ2l5R3rrfq9IHEUxw26H4X_b96j-Ad5UyUQ |
| CitedBy_id | crossref_primary_10_1016_j_brainresbull_2025_111237 |
| Cites_doi | 10.1038/s41386-019-0491-8 10.1007/s00213-017-4652-3 10.1016/0304-3959(94)90130-9 10.1016/j.coph.2016.11.007 10.1016/j.pain.2014.06.011 10.1016/j.anclin.2018.09.010 10.1124/jpet.112.201616 10.1016/j.pbb.2010.02.009 10.1080/17460441 10.1016/j.bmcl.2015.12.024 10.1124/mol.112.078659 10.3390/pharmaceutics14010055 10.1126/scisignal.aai8441 10.1016/s0376-8716(98)00067-2 10.1007/s00213-016-4368-9 10.1021/acs.jmedchem.6b00748 10.1177/0269881116689257 10.1111/bph.14805 10.1111/bph.15409 10.1038/35047086 10.1124/pr.112.007138 10.1523/JNEUROSCI.2077-05.2005 10.1016/j.cell.2017.10.035 10.1016/j.bbr.2018.01.031 10.1523/JNEUROSCI.23-32-10265.2003 10.1038/nature19112 10.1097/FBP.0000000000000634 10.1097/FBP.0000000000000378 10.1016/j.neuropharm.2020.108439 10.1021/acs.biochem.1c00466 10.1016/j.tips.2017.08.004 10.1152/ajpregu.00022.2006 10.1016/j.drugalcdep.2018.08.002 10.1016/s0165-6147(98)01279-6 10.1016/S0165-6147(03)00167-6 10.1016/j.bja.2020.06.057 10.1016/j.neuropharm.2019.01.020 10.1097/MD.0000000000004943 10.1126/scisignal.aaz3140 10.1126/science.286.5449.2495 10.17226/12910 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7QR 7TK 8FD FR3 K9. NAPCQ P64 7X8 |
| DOI | 10.1007/s00213-024-06690-x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Chemoreception Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Technology Research Database Animal Behavior Abstracts ProQuest Health & Medical Complete (Alumni) Chemoreception Abstracts Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Nursing & Allied Health Premium MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-2072 |
| EndPage | 2469 |
| ExternalDocumentID | 39333403 10_1007_s00213_024_06690_x |
| Genre | Journal Article Comparative Study |
| GrantInformation_xml | – fundername: National Institute on Drug Abuse grantid: R01-DA039167; F31-DA048586 funderid: http://dx.doi.org/10.13039/100000026 – fundername: NIDA NIH HHS grantid: R01-DA039167 – fundername: NIDA NIH HHS grantid: F31-DA048586 |
| GroupedDBID | -4W -BR .55 3SX 40D 40E 95. 95~ ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS KOW N2Q R9- RHV SBY SOJ X7M ~EX AAYXX CITATION --- -Y2 .86 .GJ .VR 04C 06C 06D 0R~ 0VY 123 199 1N0 1SB 2.D 203 28- 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2QV 2VQ 2~H 30V 36B 3O- 4.4 406 408 409 53G 5QI 5RE 5VS 67N 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDBF ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMQK ABNWP ABPLI ABQBU ABQSL ABRTQ ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPIV ACPRK ACSTC ACUHS ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFEXP AFFNX AFGCZ AFHIU AFKRA AFLOW AFOHR AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. B0M BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 DWQXO DXH EAD EAP EBC EBD EBLON EBS ECM EIF EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPAXT EPL EPS ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICJ IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2M M4Y MA- MK0 N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF- PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TN5 TSG TSK TSV TUC TUS U2A U9L UAP UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WIP WJK WK6 WK8 WOW XOL YLTOR YQJ YYP Z45 ZGI ZMTXR ZOVNA ZY4 ~8M 7QG 7QR 7TK 8FD FR3 K9. P64 7X8 |
| ID | FETCH-LOGICAL-c375t-9eaafe0f761b682612d9a3549bb9e4eb49e87ae854cf5e9112aeaba94e78130e3 |
| IEDL.DBID | U2A |
| ISSN | 0033-3158 1432-2072 |
| IngestDate | Fri Jul 11 16:54:19 EDT 2025 Sat Aug 16 21:24:53 EDT 2025 Mon Jul 21 06:02:07 EDT 2025 Tue Jul 01 04:17:02 EDT 2025 Thu Apr 24 23:08:23 EDT 2025 Fri Feb 21 02:40:17 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Self-administration SR14968 Oxycodone Fentanyl Antinociception Respiratory depression SR17018 |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-9eaafe0f761b682612d9a3549bb9e4eb49e87ae854cf5e9112aeaba94e78130e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-9133-0811 0000-0002-6426-8984 |
| PMID | 39333403 |
| PQID | 3129050308 |
| PQPubID | 47309 |
| PageCount | 17 |
| ParticipantIDs | proquest_miscellaneous_3110729090 proquest_journals_3129050308 pubmed_primary_39333403 crossref_citationtrail_10_1007_s00213_024_06690_x crossref_primary_10_1007_s00213_024_06690_x springer_journals_10_1007_s00213_024_06690_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20241200 2024-12-00 2024-Dec 20241201 |
| PublicationDateYYYYMMDD | 2024-12-01 |
| PublicationDate_xml | – month: 12 year: 2024 text: 20241200 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Psychopharmacology |
| PublicationTitleAbbrev | Psychopharmacology |
| PublicationTitleAlternate | Psychopharmacology (Berl) |
| PublicationYear | 2024 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Lacy, Strickland, Feinstein, Robinson, Smith (CR19) 2016; 233 Schmid, Kennedy, Ross, Lovell, Yue, Morgenweck (CR30) 2017; 171 Soergel, Subach, Burnham, Lark, James, Sadler (CR34) 2014; 155 Schweinteck, Faunce, Rice, Obeng, Zhang, Blough (CR31) 2019; 150 DeWire, Yamashita, Rominger, Liu, Cowan, Graczyk (CR9) 2013; 344 Zamarripa, Edwards, Qureshi, Yi, Blough, Freeman (CR41) 2018; 192 Cornelissen, Blough, Bohn, Negus, Banks (CR8) 2021 Pantouli, Grim, Schmid, Acevedo-Canabal, Kennedy, Cameron (CR23) 2021; 185 Rankovic, Brust, Bohn (CR27) 2016; 26 Pergolizzi, LeQuang, Taylor, Ossipov, Colucci, Raffa (CR26) 2018; 13 Gross, Pareta, Elkassabany (CR14) 2019; 37 Sufka (CR36) 1994; 58 Ding, Kiguchi, Perrey, Nguyen, Czoty, Hsu (CR11) 2020; 125 Rivero, Llorente, McPherson, Cooke, Mundell, McArdle (CR28) 2012; 82 Kieffer (CR16) 1999; 20 Pascual, Goicoechea, Burgos, Martin (CR24) 2010; 95 Singleton, Baptista-Hon, Edelsten, McCaughey, Camplisson, Hales (CR32) 2021; 178 Gillis, Gondin, Kliewer, Sanchez, Lim, Alamein (CR12) 2020 Altarifi, David, Muchhala, Blough, Akbarali, Negus (CR1) 2017; 31 Ding, Wang, Wang, Zhou, Li, Yan (CR10) 2016; 95 Roth, Willins, Kroeze (CR29) 1998; 51 Thomsen, Woldbye, Wortwein, Fink-Jensen, Wess, Caine (CR37) 2005; 25 Bohn, Gainetdinov, Lin, Lefkowitz, Caron (CR4) 2000; 408 Pasternak, Pan (CR25) 2013; 65 Kudla, Bugno, Podlewska, Szumiec, Wiktorowska, Bojarski, Przewlocki (CR18) 2021; 14 Townsend, Naylor, Negus, Edwards, Qureshi, McLendon, McCurdy, Kapanda, do Carmo, da Silva, Hall, Sufka, Freeman (CR38) 2017; 234 Manglik, Lin, Aryal, McCorvy, Dengler, Corder (CR21) 2016; 537 Siuda, Carr, Rominger, Violin (CR33) 2017; 32 Wang, Traub, Murphy (CR40) 2006; 291 Stahl, Bohn (CR35) 2022; 61 Bohn, Gainetdinov, Sotnikova, Medvedev, Lefkowitz, Dykstra, Caron (CR5) 2003; 23 Varadi, Marrone, Palmer, Narayan, Szabo, Le Rouzic (CR39) 2016; 59 Brust, Morgenweck, Kim, Rose, Locke, Schmid (CR6) 2016; 9 Grim, Schmid, Stahl, Pantouli, Ho, Acevedo-Canabal (CR13) 2020; 45 CR22 Kudla, Bugno, Skupio, Wiktorowska, Solecki, Wojtas, Golembiowska (CR17) 2019; 176 Armendariz, Nazarian (CR2) 2018; 343 Kenakin (CR15) 2003; 24 Chan, McCarthy, Li, Palczewski, Yuan (CR7) 2017; 38 Bohn, Lefkowitz, Gainetdinov, Peppel, Caron, Lin (CR3) 1999; 286 Legakis, Bigbee, Negus (CR20) 2018; 29 M Thomsen (6690_CR37) 2005; 25 LM Bohn (6690_CR3) 1999; 286 BL Roth (6690_CR29) 1998; 51 SM DeWire (6690_CR9) 2013; 344 TF Brust (6690_CR6) 2016; 9 JL Gross (6690_CR14) 2019; 37 AA Altarifi (6690_CR1) 2017; 31 EL Stahl (6690_CR35) 2022; 61 L Kudla (6690_CR17) 2019; 176 D Pascual (6690_CR24) 2010; 95 KJ Sufka (6690_CR36) 1994; 58 GW Pasternak (6690_CR25) 2013; 65 LP Legakis (6690_CR20) 2018; 29 CL Schmid (6690_CR30) 2017; 171 RT Lacy (6690_CR19) 2016; 233 A Manglik (6690_CR21) 2016; 537 H Ding (6690_CR11) 2020; 125 TW Grim (6690_CR13) 2020; 45 A Varadi (6690_CR39) 2016; 59 Z Ding (6690_CR10) 2016; 95 6690_CR22 LM Bohn (6690_CR4) 2000; 408 T Kenakin (6690_CR15) 2003; 24 DG Soergel (6690_CR34) 2014; 155 HCS Chan (6690_CR7) 2017; 38 EA Townsend (6690_CR38) 2017; 234 L Kudla (6690_CR18) 2021; 14 ER Siuda (6690_CR33) 2017; 32 CA Zamarripa (6690_CR41) 2018; 192 JV Pergolizzi (6690_CR26) 2018; 13 S Singleton (6690_CR32) 2021; 178 JC Cornelissen (6690_CR8) 2021 LM Bohn (6690_CR5) 2003; 23 G Rivero (6690_CR28) 2012; 82 Z Rankovic (6690_CR27) 2016; 26 A Armendariz (6690_CR2) 2018; 343 A Gillis (6690_CR12) 2020 F Pantouli (6690_CR23) 2021; 185 BL Kieffer (6690_CR16) 1999; 20 KL Schweinteck (6690_CR31) 2019; 150 X Wang (6690_CR40) 2006; 291 |
| References_xml | – volume: 45 start-page: 416 year: 2020 end-page: 425 ident: CR13 article-title: A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal publication-title: Neuropsychopharmacology doi: 10.1038/s41386-019-0491-8 – ident: CR22 – volume: 234 start-page: 2597 year: 2017 end-page: 2605 ident: CR38 article-title: Effects of Nalfurafine on the reinforcing, thermal, antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-017-4652-3 – volume: 58 start-page: 355 year: 1994 end-page: 366 ident: CR36 article-title: Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain publication-title: Pain doi: 10.1016/0304-3959(94)90130-9 – volume: 32 start-page: 77 year: 2017 end-page: 84 ident: CR33 article-title: Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2016.11.007 – volume: 155 start-page: 1829 year: 2014 end-page: 1835 ident: CR34 article-title: Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers publication-title: Pain doi: 10.1016/j.pain.2014.06.011 – volume: 37 start-page: 79 year: 2019 end-page: 91 ident: CR14 article-title: Pain management in trauma in the age of the opioid crisis publication-title: Anesthesiol Clin doi: 10.1016/j.anclin.2018.09.010 – volume: 344 start-page: 708 year: 2013 end-page: 717 ident: CR9 article-title: A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.112.201616 – volume: 95 start-page: 331 year: 2010 end-page: 337 ident: CR24 article-title: Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2010.02.009 – volume: 13 start-page: 965 year: 2018 end-page: 972 ident: CR26 article-title: Designing safer analgesics: a focus on mu-opioid receptor pathways publication-title: Expert Opin Drug Discov doi: 10.1080/17460441 – volume: 26 start-page: 241 year: 2016 end-page: 250 ident: CR27 article-title: Biased agonism: An emerging paradigm in GPCR drug discovery publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2015.12.024 – volume: 82 start-page: 178 year: 2012 end-page: 188 ident: CR28 article-title: Endomorphin-2: a biased agonist at the mu-opioid receptor publication-title: Mol Pharmacol doi: 10.1124/mol.112.078659 – volume: 14 start-page: 55 year: 2021 ident: CR18 article-title: Comparison of an addictive potential of μ-opioid receptor agonists with G Protein bias: behavioral and molecular modeling studies publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14010055 – volume: 9 start-page: ra117 year: 2016 ident: CR6 article-title: Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria publication-title: Sci Signal doi: 10.1126/scisignal.aai8441 – volume: 51 start-page: 73 year: 1998 end-page: 85 ident: CR29 article-title: G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse publication-title: Drug Alcohol Depend doi: 10.1016/s0376-8716(98)00067-2 – volume: 233 start-page: 2301 year: 2016 end-page: 2310 ident: CR19 article-title: The effects of sex, estrous cycle, and social contract on cocaine and heroin self-administration in rats publication-title: Psychopharmacology doi: 10.1007/s00213-016-4368-9 – volume: 59 start-page: 8381 year: 2016 end-page: 8397 ident: CR39 article-title: Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b00748 – volume: 31 start-page: 730 year: 2017 end-page: 739 ident: CR1 article-title: Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents publication-title: J Psychopharmacol doi: 10.1177/0269881116689257 – volume: 176 start-page: 4434 year: 2019 end-page: 4445 ident: CR17 article-title: Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine publication-title: Br J Pharmacol doi: 10.1111/bph.14805 – volume: 178 start-page: 1855 year: 2021 end-page: 1868 ident: CR32 article-title: TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available μ-opioid receptor number publication-title: Br J Pharmacol doi: 10.1111/bph.15409 – volume: 408 start-page: 720 year: 2000 end-page: 723 ident: CR4 article-title: Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence publication-title: Nature doi: 10.1038/35047086 – volume: 65 start-page: 1257 year: 2013 end-page: 1317 ident: CR25 article-title: Mu opioids and their receptors: evolution of a concept publication-title: Pharmacol Rev doi: 10.1124/pr.112.007138 – volume: 25 start-page: 8141 year: 2005 end-page: 8149 ident: CR37 article-title: Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mic publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2077-05.2005 – volume: 171 start-page: e1113 issue: 1165–1175 year: 2017 ident: CR30 article-title: Bias factor and therapeutic window correlate to predict safer opioid analgesics publication-title: Cell doi: 10.1016/j.cell.2017.10.035 – volume: 343 start-page: 21 year: 2018 end-page: 27 ident: CR2 article-title: Morphine antinociception on thermal sensitivity and place conditioning in male and female rats treated with intraplantar complete freund's adjuvant publication-title: Behav Brain Res doi: 10.1016/j.bbr.2018.01.031 – volume: 23 start-page: 10265 year: 2003 end-page: 10273 ident: CR5 article-title: Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-32-10265.2003 – volume: 537 start-page: 185 year: 2016 end-page: 190 ident: CR21 article-title: Structure-based discovery of opioid analgesics with reduced side effects publication-title: Nature doi: 10.1038/nature19112 – year: 2021 ident: CR8 article-title: Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000634 – volume: 29 start-page: 290 year: 2018 end-page: 298 ident: CR20 article-title: Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000378 – volume: 185 start-page: 108439 year: 2021 ident: CR23 article-title: Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2020.108439 – volume: 61 start-page: 1923 year: 2022 end-page: 1935 ident: CR35 article-title: Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists publication-title: Biochemistry doi: 10.1021/acs.biochem.1c00466 – volume: 38 start-page: 1016 year: 2017 end-page: 1037 ident: CR7 article-title: Designing safer analgesics via mu-opioid receptor pathways publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2017.08.004 – volume: 291 start-page: R300 year: 2006 end-page: R306 ident: CR40 article-title: Persistent pain model reveals sex difference in morphine potency publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.00022.2006 – volume: 192 start-page: 158 year: 2018 end-page: 162 ident: CR41 article-title: The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2018.08.002 – volume: 20 start-page: 19 year: 1999 end-page: 26 ident: CR16 article-title: Opioids: first lessons from knockout mice publication-title: Trends Pharmacol Sci doi: 10.1016/s0165-6147(98)01279-6 – volume: 24 start-page: 346 year: 2003 end-page: 354 ident: CR15 article-title: Ligand-selective receptor conformations revisited: the promise and the problem publication-title: Trends Pharmacol Sci doi: 10.1016/S0165-6147(03)00167-6 – volume: 125 start-page: 596 year: 2020 end-page: 604 ident: CR11 article-title: Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates publication-title: Br J Anaesth doi: 10.1016/j.bja.2020.06.057 – volume: 150 start-page: 200 year: 2019 end-page: 209 ident: CR31 article-title: Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2019.01.020 – volume: 95 start-page: e4943 year: 2016 ident: CR10 article-title: Efficacy and tolerability of oxycodone versus fentanyl for intravenous patient-controlled analgesia after gastrointestinal laparotomy: a prospective, randomized, double-blind study publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000004943 – year: 2020 ident: CR12 article-title: Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists publication-title: Sci Signal doi: 10.1126/scisignal.aaz3140 – volume: 286 start-page: 2495 year: 1999 end-page: 2498 ident: CR3 article-title: Enhanced morphine analgesia in mice lacking beta-arrestin 2 publication-title: Science doi: 10.1126/science.286.5449.2495 – volume: 58 start-page: 355 year: 1994 ident: 6690_CR36 publication-title: Pain doi: 10.1016/0304-3959(94)90130-9 – volume: 14 start-page: 55 year: 2021 ident: 6690_CR18 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14010055 – volume: 32 start-page: 77 year: 2017 ident: 6690_CR33 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2016.11.007 – volume: 125 start-page: 596 year: 2020 ident: 6690_CR11 publication-title: Br J Anaesth doi: 10.1016/j.bja.2020.06.057 – volume: 24 start-page: 346 year: 2003 ident: 6690_CR15 publication-title: Trends Pharmacol Sci doi: 10.1016/S0165-6147(03)00167-6 – volume: 344 start-page: 708 year: 2013 ident: 6690_CR9 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.112.201616 – volume: 537 start-page: 185 year: 2016 ident: 6690_CR21 publication-title: Nature doi: 10.1038/nature19112 – volume: 25 start-page: 8141 year: 2005 ident: 6690_CR37 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2077-05.2005 – volume: 408 start-page: 720 year: 2000 ident: 6690_CR4 publication-title: Nature doi: 10.1038/35047086 – volume: 9 start-page: ra117 year: 2016 ident: 6690_CR6 publication-title: Sci Signal doi: 10.1126/scisignal.aai8441 – volume: 26 start-page: 241 year: 2016 ident: 6690_CR27 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2015.12.024 – volume: 37 start-page: 79 year: 2019 ident: 6690_CR14 publication-title: Anesthesiol Clin doi: 10.1016/j.anclin.2018.09.010 – volume: 13 start-page: 965 year: 2018 ident: 6690_CR26 publication-title: Expert Opin Drug Discov doi: 10.1080/17460441 – volume: 38 start-page: 1016 year: 2017 ident: 6690_CR7 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2017.08.004 – volume: 59 start-page: 8381 year: 2016 ident: 6690_CR39 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b00748 – volume: 286 start-page: 2495 year: 1999 ident: 6690_CR3 publication-title: Science doi: 10.1126/science.286.5449.2495 – volume: 23 start-page: 10265 year: 2003 ident: 6690_CR5 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-32-10265.2003 – volume: 233 start-page: 2301 year: 2016 ident: 6690_CR19 publication-title: Psychopharmacology doi: 10.1007/s00213-016-4368-9 – volume: 65 start-page: 1257 year: 2013 ident: 6690_CR25 publication-title: Pharmacol Rev doi: 10.1124/pr.112.007138 – volume: 31 start-page: 730 year: 2017 ident: 6690_CR1 publication-title: J Psychopharmacol doi: 10.1177/0269881116689257 – volume: 171 start-page: e1113 issue: 1165–1175 year: 2017 ident: 6690_CR30 publication-title: Cell doi: 10.1016/j.cell.2017.10.035 – year: 2021 ident: 6690_CR8 publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000634 – volume: 82 start-page: 178 year: 2012 ident: 6690_CR28 publication-title: Mol Pharmacol doi: 10.1124/mol.112.078659 – volume: 150 start-page: 200 year: 2019 ident: 6690_CR31 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2019.01.020 – volume: 343 start-page: 21 year: 2018 ident: 6690_CR2 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2018.01.031 – year: 2020 ident: 6690_CR12 publication-title: Sci Signal doi: 10.1126/scisignal.aaz3140 – volume: 291 start-page: R300 year: 2006 ident: 6690_CR40 publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.00022.2006 – volume: 176 start-page: 4434 year: 2019 ident: 6690_CR17 publication-title: Br J Pharmacol doi: 10.1111/bph.14805 – volume: 45 start-page: 416 year: 2020 ident: 6690_CR13 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-019-0491-8 – volume: 95 start-page: e4943 year: 2016 ident: 6690_CR10 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000004943 – volume: 234 start-page: 2597 year: 2017 ident: 6690_CR38 publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-017-4652-3 – ident: 6690_CR22 doi: 10.17226/12910 – volume: 95 start-page: 331 year: 2010 ident: 6690_CR24 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2010.02.009 – volume: 51 start-page: 73 year: 1998 ident: 6690_CR29 publication-title: Drug Alcohol Depend doi: 10.1016/s0376-8716(98)00067-2 – volume: 178 start-page: 1855 year: 2021 ident: 6690_CR32 publication-title: Br J Pharmacol doi: 10.1111/bph.15409 – volume: 185 start-page: 108439 year: 2021 ident: 6690_CR23 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2020.108439 – volume: 155 start-page: 1829 year: 2014 ident: 6690_CR34 publication-title: Pain doi: 10.1016/j.pain.2014.06.011 – volume: 29 start-page: 290 year: 2018 ident: 6690_CR20 publication-title: Behav Pharmacol doi: 10.1097/FBP.0000000000000378 – volume: 61 start-page: 1923 year: 2022 ident: 6690_CR35 publication-title: Biochemistry doi: 10.1021/acs.biochem.1c00466 – volume: 20 start-page: 19 year: 1999 ident: 6690_CR16 publication-title: Trends Pharmacol Sci doi: 10.1016/s0165-6147(98)01279-6 – volume: 192 start-page: 158 year: 2018 ident: 6690_CR41 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2018.08.002 |
| SSID | ssj0000484 ssj0068394 |
| Score | 2.469165 |
| Snippet | Rationale
G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists... G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when... RationaleG-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2453 |
| SubjectTerms | Agonists Analgesics Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacology Animals Biomedical and Life Sciences Biomedicine Dose-Response Relationship, Drug Drug abuse Female Fentanyl Fentanyl - administration & dosage Fentanyl - pharmacology Male Narcotics Neurosciences Opioid receptors (type mu) Original Investigation Oxycodone Oxycodone - administration & dosage Oxycodone - pharmacology Pain perception Pharmacology/Toxicology Proteins Psychiatry Rats Rats, Sprague-Dawley Receptors, Opioid, mu - agonists Reinforcement Schedule Reinforcement, Psychology Respiratory Insufficiency - chemically induced Respiratory Insufficiency - drug therapy Self Administration Spiro Compounds Thiophenes |
| Title | Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein biased mu-opioid receptor agonists in male and female Sprague–Dawley rats |
| URI | https://link.springer.com/article/10.1007/s00213-024-06690-x https://www.ncbi.nlm.nih.gov/pubmed/39333403 https://www.proquest.com/docview/3129050308 https://www.proquest.com/docview/3110729090 |
| Volume | 241 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NatwwEBYlgdJLSdM_t2lQoOTSFdiW5LWPmzSbkJIQaBbSk5Hs8bLQ2Mt6N-3e-g59nT5Nn6Qz8s9S0hZ6si2PRoYZaUaemU-Mvc2tTTItc4G2wwhlYxA2tlYYbXDPYrFVUjXyxWV0NlHnN_qmLQqru2z3LiTpVuq-2I3MEcUcFVXNJ75Az3Fb094dtXgSjjbrr6LSy-YhQvvfADFLKiPTcVs382eGv9umew7nvWCps0HjHfa4dR75qJH2E_YAyl328KINj--yw6sGiHo94Nebuqp6wA_51Qaiev2U_Tjujx_kVcHRCeQLcBiqyGg64IbOj0CxuZyXO6CGHCn6qDxvE2iRjrcZIcSHQB-q5XpOgnddToXDgZiV3M7QXOb8diWq-ayaETdiXi24mVaE3ltzpLpFc-U6FuBuP84XZrqCn9--vzdfcPniOHz9jE3GJ9fHZ6I9x0FkcqiXIgFjCvCLYRTYKCbMsjwxEjemqCegwKoE4qGBWKus0ICrb2jAWJMoGMZoYkE-Z1tlVcJLxqUfQhRja5AZhWxslBhdhEUQGRlInXks6CSYZi3IOZ218Tnt4Zmd1FOUeuqknn712Lu-z7yB-Pgn9V6nGGk73etU0t88TdA_HjvoX-NEpeiLKaFaEU1AKO1-4nvsRaNQ_XAykVIqX3ps0GnYhvnfv-XV_5G_Zo9C0naXjLPHtpaLFbxBl2pp99n2aHx0dEnX008fTvbdjPoFjRoejQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fb9MwELfQJgEvaIx_gQFGQnuhlpLYTpPHaTAKrNMkWmlvkZ1cqkosqZoW6Nu-w74On4ZPwp3zp0IDJN4S53yJdGffOXf3O8Ze59YmmZa5QNthhLIxCBtbK4w2eGaxOCqpGnl8Fo2m6uOFvmiLwuou270LSbqdui92I3NEMUdFVfOJL9Bz3EVnIKZErml4tN1_FZVeNjcR2v8GiFlSGZmO27qZPzP83TbdcDhvBEudDTrZY_da55EfNdK-z25Buc9uj9vw-D47PG-AqDcDPtnWVdUDfsjPtxDVmwfsx3HffpBXBUcnkC_BYagio9mAG-ofgWJzOS9fgQZypOij8rxNoEU63maEEB8CfahWmwUJ3k15LxwOxLzkdo7mMueXa1Et5tWcuBHzasnNrCL03poj1SWaKzexAHf5ebE0szX8vLp-a77h9sXx9fVDNj15NzkeibaPg8jkUK9EAsYU4BfDKLBRTJhleWIkHkxRT0CBVQnEQwOxVlmhAXff0ICxJlEwjNHEgnzEdsqqhCeMSz-EKMbRIDMK2dgoMboIiyAyMpA681jQSTDNWpBz6rXxJe3hmZ3UU5R66qSefvfYm37OooH4-Cf1QacYabvc61TS3zxN0D8ee9U_xoVK0RdTQrUmmoBQ2v3E99jjRqH618lESql86bFBp2Fb5n__lqf_R_6S3RlNxqfp6YezT8_Y3ZA03yXmHLCd1XINz9G9WtkXbjX9AkUVHnA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtNAEF6hIlVcEJQ_Q4FFQr2QVW3vrmMfq5ZQflpFopF6s3btcRSpta3Eoc2Nd-B1eBqehJm144AKSNzszew40szujD3zfcvY69zaJNMyFxg7jFA2BmFja4XRBt9ZLI5KQiOfnEbHE_XhXJ__guJ33e7rkmSLaSCWprLZr_Nivwe-UWii-qMiBH3iC8wib-N2HJBfT8KDzV6sCIbZ3kSYC7SkzJIgZTruMDR_Vvh7nLqRfN4onLp4NLrH7naJJD9oLX-f3YJyh22fdKXyHbY3bkmpVwN-tsFYLQZ8j483dNWrB-z7YX8UIa8Kjgkhn4PjU0VF0wE3dJYEmtD1v3wBGshRoq_Q866ZFuV41x1CeogAompWNTmBm_JOOE6IWcntDENnzi-Xoqpn1Yy0kfJqzs20IibfBUepSwxdbmIB7vJzPTfTJfz4-u3IXOFWxvHxi4dsMnp7dngsujMdRCaHuhEJGFOAXwyjwEYx8ZfliZH4koo-AwqsSiAeGoi1ygoNuBOHBow1iYJhjOEW5CO2VVYlPGFc-iFEMY4GmVGoxkaJ0UVYBJGRgdSZx4K1BdOsIzynczcu0p6q2Vk9Raunzurptcfe9HPqlu7jn9K7a8dIu6W_SCV92dNEA-SxV_3PuGipEmNKqJYkExBju5_4HnvcOlT_OJlIKZUvPTZYe9hG-d__y9P_E3_JtsdHo_TT-9OPz9idkBzf9ejssq1mvoTnmGk19oVbTD8BOB8irA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+reinforcing%2C+antinociceptive%2C+and+respiratory+depressant+effects+of+prototypical+and+G-protein+biased+mu-opioid+receptor+agonists+in+male+and+female+Sprague%E2%80%93Dawley+rats&rft.jtitle=Psychopharmacology&rft.au=Zamarripa%2C+C.+Austin&rft.au=Pareek%2C+Tanya&rft.au=Pham%2C+Loc+M.&rft.au=Blough%2C+Bruce+E.&rft.date=2024-12-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=241&rft.issue=12&rft.spage=2453&rft.epage=2469&rft_id=info:doi/10.1007%2Fs00213-024-06690-x&rft.externalDocID=10_1007_s00213_024_06690_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |